Illumina, Inc. (Nasdaq: ILMN) has announced its financial results for the first quarter of fiscal year 2026, showcasing robust performance across key metrics. The company reported a revenue of $1.09 billion, marking a 4.8% increase from the same quarter last year, driven by solid demand for its products and services.

1. Key Financial Highlights

Revenue: The company achieved $1.09 billion in revenue for Q1 2026, an increase of 4.8% year-over-year, with a rest-of-world (ROW) organic revenue growth of 3.5%.

Profitability: Illumina's GAAP operating margin stood at 19.2%, while the non-GAAP operating margin reached 21.9%. The GAAP diluted earnings per share (EPS) was reported at $0.87, and the non-GAAP diluted EPS was $1.15.

Share Repurchase Authorization: On April 28, 2026, Illumina's Board of Directors authorized an additional $1.5 billion in share repurchases, signaling confidence in the company’s financial health and future growth prospects.

Jacob Thaysen, CEO of Illumina, commented, "Illumina delivered a strong start to 2026, reflecting the strength of the Illumina ecosystem and progress against our strategy. Demand for NovaSeq X is increasing as we help our clinical customers expand into new application areas. With our strong first quarter performance, we are raising our full-year revenue and EPS guidance."

2. Revised Fiscal Year 2026 Guidance

In light of its strong Q1 results, Illumina has updated its guidance for fiscal year 2026:

Total Revenue: Expected to be in the range of $4.52 billion to $4.62 billion, a $20 million increase at the mid-point compared to prior guidance.

Reported Revenue Growth: Projected at 4%-6%, with ROW organic revenue growth anticipated at 2%-4%, both remaining unchanged from previous estimates.

Non-GAAP Operating Margin: Expected to be between 23.4% and 23.6%, an improvement from prior guidance of 23.3% to 23.5%.

Non-GAAP Diluted EPS: Forecasted to be between $5.15 and $5.30, up from the earlier guidance of $5.05 to $5.20.

3. Detailed Financial Performance

First Quarter Results Overview

The financial statements reflect a solid operational performance:

Gross Margin: The gross margin for Q1 2026 was 66.1%, compared to 65.6% in Q1 2025, while the non-GAAP gross margin improved to 68.2% from 67.4%.

Operating Profit: The company reported an operating profit of $209 million, up from $164 million in the prior year, resulting in an operating margin of 19.2%.

Earnings Per Share: The diluted EPS increased from $0.82 in Q1 2025 to $0.87 in Q1 2026, with non-GAAP diluted EPS rising from $0.97 to $1.15.

Illumina's free cash flow for the quarter was $251 million, compared to $208 million in the same quarter last year. The company ended the period with $1.16 billion in cash, cash equivalents, and short-term investments.

Balance Sheet Strength

As of March 29, 2026, Illumina reported total assets of $6.56 billion, with total current assets of $2.74 billion. The company maintained a healthy balance sheet, with current liabilities totaling $1.57 billion, leading to a stockholders' equity of $2.68 billion.

4. Looking Ahead

The conference call scheduled for April 30, 2026, at 1:30 PM PT (4:30 PM ET) will provide further insights into Illumina's strategic initiatives and market outlook. Investors and analysts are encouraged to participate in this call as the company discusses its vision for the future and responds to market dynamics.

Illumina continues to focus on unlocking the potential of genomic technology, enhancing human health through innovation, and expanding its leadership position in the life sciences and clinical diagnostics markets. As the demand for genetic sequencing solutions continues to grow, Illumina is well-positioned for sustained growth and success in the coming quarters.

Original press release